Atrium Health Union
- Type
- Teaching hospital
- Where
- MONROE, NC
- Medicare CCN
- 340130
- Received
- $6,587,512 in 518 records, 2023 ($461,363 general, $6,126,149 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 31 | $461,363 |
| 2023 | Research payment | 487 | $6,126,149 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 487 | $6,126,149 |
| Consulting Fee | 8 | $217,942 |
| Grant | 1 | $192,661 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $25,000 |
| Debt forgiveness | 17 | $15,910 |
| Space rental or facility fees (teaching hospital only) | 4 | $9,850 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-31 | Gilead Sciences, Inc. | $192,661 | Grant | Cash or cash equivalent | 2023 | ||
| 2023-12-31 | Merck Sharp & Dohme LLC | $54,485 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | ToPCourT# A Phase II Trial of Trilaciclib, Pembrolizumab, Carboplatin, and Gemcitabine in Metastatic Triple-Negative Bre | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $36,141 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $27,378 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $25,594 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $23,975 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK 7684A Vibostolimab with | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $7,098 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $5,842 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $4,299 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemothera | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $3,791 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently | 2023 |
| 2023-12-31 | ABBVIE INC. | $3,565 | Research payment | In-kind items and services | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Mu | 2023 | |
| 2023-12-31 | Merck Sharp & Dohme LLC | $2,368 | Research payment | In-kind items and services | LAGEVRIO Biological, INFECTIOUS DISEASE | A Phase 2,3 Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety and Pharmacokin | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $158 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial of Single Agent Pembrolizumab MK-3475 in Subjects with Recurrent or Metastatic Head and Neck S | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $21 | Research payment | In-kind items and services | ZERBAXA Drug, INFECTIOUS DISEASE | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF INTRAVENOUS CEF | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | $1 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PHASE 3 STUDY TO ASSESS THE SAFETY AND EFFICACY OF INTRAVENOUS CEF | 2023 |
| 2023-12-25 | Janssen Research & Development, LLC | $15,496 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Safety and Efficacy Study of JNJ-68284528 (ciltacabtagene autoleucel) Out-of-Specification (OOS) for Commercial Releas | 2023 |
| 2023-12-25 | Janssen Research & Development, LLC | $13,489 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2023 |
| 2023-12-23 | PFIZER INC. | $89,551 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-12-21 | Janssen Research & Development, LLC | $19,719 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2023 |
| 2023-12-21 | Janssen Research & Development, LLC | $2,061 | Research payment | Cash or cash equivalent | A Multi arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myeloma | 2023 | |
| 2023-12-19 | Novo Nordisk Inc | $2,850 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2023 | ||
| 2023-12-19 | ABBVIE INC. | $25 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | A Long-Term Registry of Humira(Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) | 2023 |
| 2023-12-18 | Celgene Corporation | $14,627 | Research payment | Cash or cash equivalent | PhI Ide-Cel RRMM Combo (bb2121-MM-007; KarMMa-7) - An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose | 2023 | |
| 2023-12-18 | Janssen Research & Development, LLC | $5,454 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2023 | |
| 2023-12-18 | Janssen Research & Development, LLC | $2,657 | Research payment | Cash or cash equivalent | A Phase 1 Dose Escalation Study of JNJ75229414 a Chimeric Antigen Receptor T cell CART Therapy Directed Against KLK2 for | 2023 | |
| 2023-12-18 | Ethicon Endo-Surgery Inc. | $2,450 | Research payment | Cash or cash equivalent | Enseal Device, Energy | A Prospective, Single-Arm Multi-Center Study of the ENSEALX1 Curved Jaw Tissue Sealer and Generator G11 in Upper Gastroi | 2023 |
| 2023-12-18 | Janssen Research & Development, LLC | $1,092 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk | 2023 |
| 2023-12-18 | Janssen Research & Development, LLC | $596 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2023 |
| 2023-12-18 | Janssen Research & Development, LLC | $442 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2023 |
| 2023-12-18 | Immedica Pharma US, Inc. | $91 | Research payment | Cash or cash equivalent | A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in St | 2023 | |
| 2023-12-15 | Janssen Research & Development, LLC | $500 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-15 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-12-14 | CSL Behring | $107,280 | Research payment | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-12-14 | Janssen Research & Development, LLC | $5,055 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3 Study of the Efficacy Safety and Pharmacokinetics of Ustekinumab as Open label Intravenous Induction Treatment | 2023 |
| 2023-12-14 | ABBVIE INC. | $3,000 | Research payment | Cash or cash equivalent | Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of | 2023 | |
| 2023-12-14 | Janssen Research & Development, LLC | $1,814 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Openlabel Intravenous Induction Treatment | 2023 |
| 2023-12-14 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2023 |
| 2023-12-13 | CSL Behring | $183,002 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-12-13 | ABBVIE INC. | $88 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Cr | 2023 |
| 2023-12-11 | Merck Sharp & Dohme LLC | $18,036 | Research payment | Cash or cash equivalent | BRIDION Drug, NEUROSCIENCE | The POUR Study# Effects of Neuromuscular Reversal Agents on Postoperative Urinary Retention POUR Following Laparoscopic | 2023 |
| 2023-12-11 | Janssen Research & Development, LLC | $13,088 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2023 | |
| 2023-12-11 | Janssen Research & Development, LLC | $5,004 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2023 | |
| 2023-12-07 | Genmab U.S., Inc. | $23,242 | Research payment | Cash or cash equivalent | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With | 2023 | |
| 2023-12-07 | ABBVIE INC. | $1,228 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participa | 2023 |
| 2023-12-04 | ABBVIE INC. | $10,732 | Research payment | Cash or cash equivalent | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination Wi | 2023 | |
| 2023-11-30 | Artivion, Inc. | $11,055 | Research payment | Cash or cash equivalent | AMDS-Ascyrus Medical Device, Cardiovascular and vascular surgery | PERSEVERE | 2023 |
| 2023-11-30 | BIOTRONIK INC. | $1,990 | Debt forgiveness | Cash or cash equivalent | 2023 | ||
| 2023-11-28 | CSL Behring | $44,700 | Research payment | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-11-22 | Intercept Pharma Europe Ltd. | $11,543 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2023 |
| 2023-11-22 | Genmab A/S | $200 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-11-20 | Janssen Research & Development, LLC | $15,171 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Phase II Study of Daratumumab Combined with Carfilzomib Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myelo | 2023 |
| 2023-11-17 | Ethicon Endo-Surgery Inc. | $13,777 | Research payment | Cash or cash equivalent | Neuwave Device, Ablation System | Prospective Analysis of In Vivo Laparoscopic Microwave Ablation Thermodynamics in Hepato-Pancreato-Biliary Solid Tumors | 2023 |
| 2023-11-16 | Janssen Research & Development, LLC | $13,933 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2023 |
| 2023-11-16 | Pharmacyclics LLC, an AbbVie Company | $147 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2023 |
| 2023-11-14 | ABBVIE INC. | $4,512 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis | 2023 |
| 2023-11-10 | Penumbra, Inc. | $541 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIDE | 2023 |
| 2023-11-09 | Genmab U.S., Inc. | $63,348 | Research payment | Cash or cash equivalent | First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With | 2023 | |
| 2023-11-09 | CSL Behring | $44,700 | Research payment | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-11-09 | ABBVIE INC. | $1,207 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis | 2023 |
| 2023-11-09 | ABBVIE INC. | $160 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Cr | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $370 | Research payment | Cash or cash equivalent | Rivacor 7 DR-T Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $332 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $283 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $283 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $206 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Rivacor 7 DR-T Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $78 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $41 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $31 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Sentus Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Plexa ProMRI Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Acticor 7 VR-T DX Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-07 | BIOTRONIK INC. | $26 | Research payment | Cash or cash equivalent | Rivacor 7 DR-T Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2023 |
| 2023-11-01 | GLOBAL BLOOD THERAPEUTICS, INC. | $10,383 | Research payment | Cash or cash equivalent | OXBRYTA Drug, HEMATOLOGY | AN OPEN LABEL OBSERVATIONAL PROSPECTIVE REGISTRY OF PARTICIPANTS WITH SICKLE CELL DISEASE SCD TREATED WITH OXBRYTA VOXEL | 2023 |
| 2023-10-30 | Janssen Research & Development, LLC | $17,644 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-10-30 | Olympus America Inc. | $3 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-10-30 | Olympus America Inc. | $1 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-10-29 | Olympus America Inc. | $20 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-10-27 | CSL Behring | $3,000 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-10-27 | Janssen Research & Development, LLC | $2,236 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2023 | |
| 2023-10-27 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-10-27 | CSL Behring | $500 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-10-27 | CSL Behring | $400 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-10-26 | Genmab U.S., Inc. | $15,544 | Research payment | Cash or cash equivalent | An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Ot | 2023 | |
| 2023-10-25 | Celgene Corporation | $104,220 | Research payment | Cash or cash equivalent | ABECMA Biological, Oncology | PhIIb Ide-Cel Multi-cohort MM (1L, 2L, 4L+) KarMma-2 (bb2121-MM-002) - A phase 2, multi-cohort, open-label, multicenter | 2023 |
| 2023-10-25 | CSL Behring | $44,700 | Research payment | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-10-23 | Janssen Research & Development, LLC | $57,217 | Research payment | Cash or cash equivalent | ERLEADA Drug, Oncology | An Open label Multi Center Phase 1b Study of JNJ63723283 a PD1 Inhibitor Administered in Combination with Apalutamide in | 2023 |
| 2023-10-23 | Janssen Research & Development, LLC | $3,200 | Research payment | Cash or cash equivalent | A Phase 3 Study of Erdafitinib Compared to Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial | 2023 | |
| 2023-10-20 | Janssen Research & Development, LLC | $31,374 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2023 | |
| 2023-10-19 | Janssen Research & Development, LLC | $4,673 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3 Study of the Efficacy Safety and Pharmacokinetics of Ustekinumab as Open label Intravenous Induction Treatment | 2023 |
| 2023-10-17 | CSL Behring | $35,760 | Research payment | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-10-17 | Immedica Pharma US, Inc. | $4,150 | Research payment | Cash or cash equivalent | A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in St | 2023 | |
| 2023-10-17 | Immedica Pharma US, Inc. | $859 | Research payment | Cash or cash equivalent | A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in St | 2023 | |
| 2023-10-16 | Janssen Research & Development, LLC | $28,926 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2023 | |
| 2023-10-12 | Silk Road Medical, Inc. | $4,111 | Research payment | Cash or cash equivalent | ENROUTE Transcarotid Stent Device, Cardiology/Vascular Diseases | Roadster 3 | 2023 |
| 2023-10-12 | ABBVIE INC. | $1,717 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participa | 2023 |
| 2023-10-11 | Intercept Pharma Europe Ltd. | $5,208 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2023 |
| 2023-10-06 | CSL Behring | $310,374 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-10-05 | Janssen Research & Development, LLC | $17,121 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleu | 2023 |
| 2023-10-05 | Olympus America Inc. | $5,582 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-10-05 | Olympus America Inc. | $186 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-10-04 | Merck Sharp & Dohme LLC | $249,999 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | ToPCourT# A Phase II Trial of Trilaciclib, Pembrolizumab, Carboplatin, and Gemcitabine in Metastatic Triple-Negative Bre | 2023 |
| 2023-10-02 | Janssen Research & Development, LLC | $2,200 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2023 |
| 2023-09-29 | CSL Behring | $44,700 | Research payment | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-09-26 | ABBVIE INC. | $1,300 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) | 2023 |
| 2023-09-22 | Janssen Research & Development, LLC | $5,478 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3 Study of the Efficacy Safety and Pharmacokinetics of Ustekinumab as Open label Intravenous Induction Treatment | 2023 |
| 2023-09-22 | Janssen Research & Development, LLC | $2,236 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2023 | |
| 2023-09-22 | Pharmacyclics LLC, an AbbVie Company | $461 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2023 |
| 2023-09-22 | Pharmacyclics LLC, an AbbVie Company | $461 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2023 |
| 2023-09-22 | Pharmacyclics LLC, an AbbVie Company | $253 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2023 |
| 2023-09-22 | Janssen Research & Development, LLC | $242 | Research payment | Cash or cash equivalent | A Phase 1 First in Human Open Label Dose Escalation Study of JNJ64007957 a Humanized BCMA x CD3 DuoBody Antibody in Subj | 2023 | |
| 2023-09-21 | Janssen Research & Development, LLC | $11,862 | Research payment | Cash or cash equivalent | A Phase 1 Dose Escalation Study of JNJ75229414 a Chimeric Antigen Receptor T cell CART Therapy Directed Against KLK2 for | 2023 | |
| 2023-09-21 | ABBVIE INC. | $11,571 | Research payment | Cash or cash equivalent | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) | 2023 | |
| 2023-09-21 | Immedica Pharma US, Inc. | $2,359 | Research payment | Cash or cash equivalent | A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in St | 2023 | |
| 2023-09-21 | Immedica Pharma US, Inc. | $350 | Research payment | Cash or cash equivalent | A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intravenous Ganaxolone in St | 2023 | |
| 2023-09-20 | Intercept Pharma Europe Ltd. | $1,806 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2023 |
| 2023-09-20 | Genmab A/S | $180 | Research payment | Cash or cash equivalent | Epkinly Drug, Oncology | A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody-CD3xCD20) | 2023 |
| 2023-09-15 | Pacira Pharmaceuticals Incorporated | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Exparel Drug, Pain Management | 2023 | |
| 2023-09-14 | CSL Behring | $44,700 | Research payment | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-09-13 | Intercept Pharma Europe Ltd. | $21,284 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2023 |
| 2023-09-13 | Gilead Sciences, Inc. | $15,700 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi | 2023 |
| 2023-09-13 | ABBVIE INC. | $6,155 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participa | 2023 |
| 2023-09-13 | ABBVIE INC. | $3,206 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis | 2023 |
| 2023-09-12 | Celgene Corporation | $195,592 | Research payment | Cash or cash equivalent | PhIIb Ide-Cel Multi-cohort MM (1L, 2L, 4L+) KarMma-2 (bb2121-MM-002) - A phase 2, multi-cohort, open-label, multicenter | 2023 | |
| 2023-09-11 | E.R. Squibb & Sons, L.L.C. | $384,392 | Research payment | Cash or cash equivalent | PILOT- 2L TNE 017006 - A Phase 2 study of JCAR017 as Second-Line Therapy in Adult Patients with Aggressive B-cell NHL | 2023 | |
| 2023-09-11 | Janssen Research & Development, LLC | $34,098 | Research payment | Cash or cash equivalent | A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations | 2023 | |
| 2023-09-11 | Janssen Research & Development, LLC | $298 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2023 |
| 2023-09-04 | Janssen Research & Development, LLC | $800 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Phase 3 Randomized Multi Center Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High risk | 2023 |
| 2023-09-01 | USWM, LLC | $40,188 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-01 | USWM, LLC | $40,188 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-08-31 | Tanabe Pharma America, Inc. | $585 | Research payment | Cash or cash equivalent | RADICAVA Drug, AMYOTROPHIC LATERAL SCLEROSIS | HOME-BASED SPIROMETRY THROUGH TELEMEDICINE IN AMYOTROPIC LATERAL SCLEROSIS | 2023 |
| 2023-08-31 | Tanabe Pharma America, Inc. | $405 | Research payment | Cash or cash equivalent | RADICAVA Drug, AMYOTROPHIC LATERAL SCLEROSIS | HOME-BASED SPIROMETRY THROUGH TELEMEDICINE IN AMYOTROPIC LATERAL SCLEROSIS | 2023 |
| 2023-08-29 | CSL Behring | $44,700 | Research payment | In-kind items and services | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2023 |
| 2023-08-29 | Penumbra, Inc. | $541 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | STRIDE | 2023 |
| 2023-08-28 | Janssen Research & Development, LLC | $66,686 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2023 |
The latest 200 records of 518.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Monroe, NC, county Union County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Monroe, NC | County Union County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 36,759 | 250,958 | 10,730,404 |
| Population, 2020 census P1 | 34,562 | 238,267 | 10,439,388 |
| Median age B01002 | 35.5 | 39.2 | 39.1 |
| Under 18 B01001 | 24.5% | 25.6% | 21.8% |
| 65 and over B01001 | 14.9% | 13.5% | 17.2% |
| Households B11001 | 12,620 | 84,237 | 4,282,345 |
| Foreign born B05002 | 17.8% | 12.2% | 9.1% |
| Median household income B19013 | $72,540 | $102,900 | $72,388 |
| Median family income B19113 | $80,817 | $118,218 | $90,290 |
| Per capita income B19301 | $31,089 | $46,949 | $41,385 |
| Poverty rate B17001 | 13.3% | 7.7% | 13.0% |
| Unemployment rate B23025 | 4.6% | 4.2% | 4.7% |
| Civilian labor force B23025 | 18,613 | 132,592 | 5,336,863 |
| Mean commute (minutes) B08013 | 30.1 | 29.8 | 25.1 |
| Bachelor's degree or higher B15003 | 24.1% | 40.5% | 35.7% |
| Housing units B25001 | 13,469 | 88,851 | 4,895,668 |
| Owner-occupied B25003 | 61.6% | 81.6% | 66.6% |
| Renters B25003 | 38.4% | 18.4% | 33.4% |
| Median home value B25077 | $309,100 | $417,300 | $288,900 |
| Median gross rent B25064 | $1,246 | $1,496 | $1,228 |
| White, not Hispanic B03002 | 43.7% | 66.8% | 60.0% |
| Black B03002 | 19.7% | 10.9% | 20.0% |
| Hispanic or Latino B03002 | 30.9% | 13.4% | 11.3% |
| Asian B03002 | 1.0% | 4.5% | 3.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Monroe, NC.
Comments